Genome Balance Sheet Health
Financial Health criteria checks 5/6
Genome has a total shareholder equity of ₩113.5B and total debt of ₩21.6B, which brings its debt-to-equity ratio to 19.1%. Its total assets and total liabilities are ₩162.1B and ₩48.5B respectively.
Key information
19.1%
Debt to equity ratio
₩21.63b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩86.27b |
| Equity | ₩113.52b |
| Total liabilities | ₩48.54b |
| Total assets | ₩162.06b |
Financial Position Analysis
Short Term Liabilities: A314130's short term assets (₩97.0B) exceed its short term liabilities (₩28.2B).
Long Term Liabilities: A314130's short term assets (₩97.0B) exceed its long term liabilities (₩20.3B).
Debt to Equity History and Analysis
Debt Level: A314130 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A314130's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A314130 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A314130 has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 33.4% each year.